Matthew Christopher

Trials

Studies that name Matthew Christopher as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:55 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04582864 · Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

  Washington University School of Medicine · terminated · Relapsed Acute Myeloid Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 16:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• MUTANT AND WILD TYPE WT1 IN AML
  K08CA222630 · NCI · WASHINGTON UNIVERSITY · fiscal years 2017 to 2021 · $137,729 awarded in 2021
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Core A: Biospecimen Processing
  P50CA171963 · NCI · WASHINGTON UNIVERSITY · PI MEAGAN JACOBY · fiscal years 2013 to 2026
  Named on NCT04582864